The U.S. Food and Drug Administration (FDA) has approved biosimilar products for the reference brand name medication, Actemra. Biosimilars for Actemra are available in the market and offer additional safe and cost-effective options for management of several autoimmune disorders.
Effective Jan 1, 2025, Tyenne will be the preferred biosimilar product for Actemra on all Blue Cross Blue Shield of North Dakota (BCBSND) formularies. Actemra will be removed from formularies and will be a non-preferred medication. Current coverage for Actemra will remain the same through Dec. 31, 2024.
Members with existing Actemra Prior Authorization (PA) approvals will be able to fill Tyenne starting Jan. 1, 2025, through the remainder of the original Actemra PA expiration date. Existing PA approvals for Actemra will be terminated Jan. 31, 2025. Utilization Management policies will be updated to reflect the formulary changes and will be available through www.bcbsnd.com on Jan. 1, 2025.
Processing...
Please wait while your form is being submitted